Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · IEX Real-Time Price · USD
6.17
+0.30 (5.11%)
At close: May 3, 2024, 4:00 PM
6.20
+0.03 (0.49%)
After-hours: May 3, 2024, 7:58 PM EDT
Ocular Therapeutix Revenue
In the year 2023, Ocular Therapeutix had annual revenue of $58.44M with 13.49% growth. Revenue in the quarter ending December 31, 2023 was $14.80M with 5.16% year-over-year growth.
Revenue (ttm)
$58.44M
Revenue Growth
+13.49%
P/S Ratio
16.33
Revenue / Employee
$218,888
Employees
267
Market Cap
954.66M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
Dec 31, 2019 | 4.23M | 2.24M | 112.41% |
Dec 31, 2018 | 1.99M | 67.00K | 3.48% |
Dec 31, 2017 | 1.92M | 36.00K | 1.91% |
Dec 31, 2016 | 1.89M | 137.00K | 7.83% |
Dec 31, 2015 | 1.75M | 978.00K | 126.68% |
Dec 31, 2014 | 772.00K | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 10.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 1.99B |
Pharming Group | 272.57M |
Aurinia Pharmaceuticals | 175.51M |
Atrion | 169.33M |
Arcturus Therapeutics Holdings | 166.80M |
OrthoPediatrics | 148.73M |
Y-mAbs Therapeutics | 84.82M |
Mobile-health Network Solutions | 7.87M |
OCUL News
- 23 hours ago - Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 - GlobeNewsWire
- 2 days ago - Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 - GlobeNewsWire
- 15 days ago - Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy - GlobeNewsWire
- 18 days ago - Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO - GlobeNewsWire
- 24 days ago - Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics - GlobeNewsWire
- 27 days ago - Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) - GlobeNewsWire
- 7 weeks ago - Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results - GlobeNewsWire